Monday, October 23, 2023

Hope for Long COVID sufferers

Plus more health news |

Email not displaying correctly? View it in your browser.
  
Long COVID research is in its 'most hopeful' phase yet
By Jamie Ducharme
Health Correspondent

Over the past three years, thousands of studies on Long COVID have been published. But very few have led to tangible benefits for the millions of people living with this often-debilitating condition.

It’s too soon to make any concrete promises, but researchers expect that to change. “In the short history of studying this disease, this is probably the most hopeful moment we’ve ever had,” researcher Christoph Thaiss told me for a new story.

Within the past couple months, two large studies—one co-authored by Thaiss—have found potential biomarkers that could make it easier to diagnose Long COVID. That’s big on its own, since lots of people are misdiagnosed or entirely missed by physicians who don’t have much experience in Long COVID. But it also opens the doors to potential treatments, because understanding what causes a condition makes it that much easier to get it under control.

READ MORE

Share This Story
What Else to Read
Why Better Community Engagement is Key to The Future of Clean Tech
By Justin Worland
Engaging communities makes projects more likely to succeed in the short term and makes them more sustainable investments in the long run.
Read More »
This Is the Best Time of Day to Work Out, According to Science
By Jamie Ducharme
If you want to optimize your workouts to get the widest range of benefits, you might want to try exercising in the morning. (Originally published in 2019.)
Read More »
What We Know About Leaky Gut Syndrome
By Elaine K. Howley
Leaky gut is a condition in which the lining of the intestines become inflamed, damaged, or irritated.
Read More »
Why Spicy Food Makes Your Nose Run—and Why It's Great for You
By Markham Heid
A plant compound called capsaicin has an ability to combat pain. (Originally published in 2019.)
Read More »
5 Ways to Keep Your Brain Sharp As You Age
By Matt Fuchs
An aging mind isn't a weak one. (Originally published in 2021.)
Read More »
ONE LAST READ
Ozempic maker Novo Nordisk is too big for Denmark

Novo Nordisk, the Denmark-based maker of blockbuster drugs Ozempic and Wegovy, is a very big fish in very small pond. As Stephen Wilmot reports in the Wall Street Journal, Novo's shares are overwhelming the stock index of Danish companies, creating a peculiar a set of problems for Danish investors.

Read More »

If you were forwarded this and want to sign up to receive it daily, click here.

Today's newsletter was written by Jamie Ducharme and Oliver Staley, and edited by Oliver.

 
 
 
 
 
 

No comments:

Post a Comment